We further evaluated the effect of carfilzomib, a proteasome inhibitor suppressing FOXM1 protein that we identified in this study, in combination with a monoclonal antibody targeting VEGFR2 on HCC growth. Here, KDR is linked to hepatocellular carcinoma.